Sandbox

Probando

<R output="html" iframe="width:100%;height:250px;"> prob=0.15; nmin=1; nmax=15; x=6 m <-pbinom(rep(0:x, each = nmax-nmin+1), rep(nmin:nmax,x), prob) dim(m) <- c(nmax-nmin+1,x+1) m <- t(m) colnames(m) <- format(nmin:nmax) rownames(m) <- format(0:x) outHTML(rhtml, m, title="x\n", format="f", digits=4) </R>

<R output="display" iframe="width:400px;height:400px"> pdf(rpdf, width=5, height=5) n <- 10 prob <- 0.2 x <- seq(0, n, 1) p <- dbinom(x, n, prob) param <- list(n, prob) main <- c("Binomialverteilung - Wahrscheinlichkeitsfunktion", paste (c("Stichprobenumfang n", "Wahrscheinlichkeit p"), param, sep="=")) plot(x,p, type="h", main=main) </R>

<R>1:20</R>

$\int _{-N}^{N}e^{x}\,dx$

hola [1]

1. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, and Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004 Dec;22(12):1567-72. DOI:10.1038/nbt1037 |
2. Ubhayasekera W, Muñoz IG, Vasella A, Ståhlberg J, and Mowbray SL. Structures of Phanerochaete chrysosporium Cel7D in complex with product and inhibitors. FEBS J. 2005 Apr;272(8):1952-64. DOI:10.1111/j.1742-4658.2005.04625.x |

3. Casajuana J, Aragonès R, Ariza F. Significado clínico de un PSA elevado FMC 2004;11(10) 604-13.

4. Etzioni RD, Ankerst DP, Weiss NS, Inoue LY, and Thompson IM. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence. J Natl Cancer Inst. 2007 Oct 17;99(20):1510-5. DOI:10.1093/jnci/djm171 |
5. Ilic D, O'Connor D, Green S, and Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006 Jul 19(3):CD004720. DOI:10.1002/14651858.CD004720.pub2 |
6. Boyd SD and Narayan P. Management of benign prostatic hyperplasia. West J Med. 1994 Feb;160(2):165-6.
7. Hoogendam A, Buntinx F, and de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract. 1999 Dec;16(6):621-6. DOI:10.1093/fampra/16.6.621 |
8. Bereczky Z, Bolus M, Chetty P, du Toit W, Enslin J, Haffejee M, Heyns C, Hyams D, Kirstein D, Mackenzie M, Mamine A, Mutambirwa S, Niemand B, Opperman C, Pontin A, Reif S, Sauer F, Segone A, Smart D, Steenkamp P, Stellmacher G, van Wijk F, Wentzel S, and South African Urological Association. Management of benign prostatic hyperplasia - South African Urological Association Guideline. S Afr Med J. 2006 Dec;96(12 Pt 3):1275-9.
9. Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, and Ohl DA. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract. 2007 Sep;61(9):1535-46. DOI:10.1111/j.1742-1241.2007.01491.x |
10. Algaba F, Trias I, and Arce Y. Natural history of prostatic carcinoma: the pathologist's perspective. Recent Results Cancer Res. 2007;175:9-24. DOI:10.1007/978-3-540-40901-4_2 |
11. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007 Dec;70(6):1117-20. DOI:10.1016/j.urology.2007.07.019 |
12. Webber R. Benign prostatic hyperplasia. Clin Evid. 2006 Jun(15):1213-26.
13. Wilt T. Prostate cancer (non-metastatic). Clin Evid. 2003 Dec(10):1023-38.
14. Marzo Castillejo M, Cierco Peguera P, and Bonfill Cosp X. [Prostate cancer screening]. Aten Primaria. 2001 Oct 31;28(7):468-71. DOI:10.1016/s0212-6567(01)70423-4 |
15. Roobol MJ, Kranse R, de Koning HJ, and Schröder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology. 2004 Feb;63(2):309-13; discussion 313-5. DOI:10.1016/j.urology.2003.09.083 |
16. Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, and Yamanaka H. Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. Urology. 2001 Dec;58(6):994-8. DOI:10.1016/s0090-4295(01)01409-1 |
17. Ilic D and Green S. Screening for prostate cancer in younger men. BMJ. 2007 Dec 1;335(7630):1105-6. DOI:10.1136/bmj.39385.491424.80 |
18. Lin KW and Duane MR. Are some screening tests doing more harm than good?. Am Fam Physician. 2007 Aug 1;76(3):351-2.
19. Irwig L, McCaffery K, Salkeld G, and Bossuyt P. Informed choice for screening: implications for evaluation. BMJ. 2006 May 13;332(7550):1148-50. DOI:10.1136/bmj.332.7550.1148 |
20. Edwards A, Unigwe S, Elwyn G, and Hood K. Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ. 2003 Sep 27;327(7417):703-9. DOI:10.1136/bmj.327.7417.703 |
21. U.S. Preventive Services Task Force. Screening for prostate cancer: recommendations and rationale. Am Fam Physician. 2003 Feb 15;67(4):787-92.
22. Sackett DL. The arrogance of preventive medicine. CMAJ. 2002 Aug 20;167(4):363-4.
23. Welch HG. Right and wrong reasons to be screened. Ann Intern Med. 2004 May 4;140(9):754-5. DOI:10.7326/0003-4819-140-9-200405040-00016 |
24. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, and Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006 Aug;52(8):1568-74. DOI:10.1373/clinchem.2006.069039 |
25. Baade PD, Coory MD, and Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004 Apr;15(3):237-41. DOI:10.1023/B:CACO.0000024212.66334.26 |
26. Walsh PC, DeWeese TL, and Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med. 2007 Dec 27;357(26):2696-705. DOI:10.1056/NEJMcp0706784 |
27. Rao AR, Motiwala HG, and Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008 Jan;101(1):5-10. DOI:10.1111/j.1464-410X.2007.07138.x |
28. Gonzalgo ML and Carter HB. Update on PSA testing. J Natl Compr Canc Netw. 2007 Aug;5(7):737-42. DOI:10.6004/jnccn.2007.0065 |
29. Djavan B, Rocco B, Stangelberger A, De Cobelli O, and Marberger M. Is the era of prostate-specific antigen over?. BJU Int. 2007 Jul;100 Suppl 2:8-10. DOI:10.1111/j.1464-410X.2007.06944.x |
30. Thompson IM and Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007 Jun 19;176(13):1853-8. DOI:10.1503/cmaj.060955 |

1. 2007ju1 pmid=17509297
2. 2007afp pmid=17492070
3. 2007ju pmid=17499293
4. 2007clt pmid=17292541
5. 2007mcp pmid=17290734
6. 2006aeu1 pmid=17283721
7. 2007cl pmid=17258389
8. 2007p pmid=17143882
9. 2007bjui pmid=17550409
10. 2007urol pmid=17382151
11. 2005wimj pmid=15999885
12. 2004bju pmid=14678366
13. 2002can pmid=12365027
14. NICE1 Guidance for ...Outcomes in Urological The Research Evidence NICE
15. 2006oncol pmid=16601365
16. 2006bju pmid=16566811
17. 2002cpc pmid=15046699
18. 2003jafp pmid=12665174
19. 2002ptt pmid=12111706
20. 2000jgim pmid=11089718
21. 2006urol pmid=16600352
22. 2006ui pmid=16401916
23. 2006upur pmid=16504254
24. cocaid pmid=12804407
25. 2006ijcp pmid=17109668
26. tramf tacto rectal amf
27. cks hbp